Avalanche Biotechnologies reports weak data
June 16, 2015 at 15:14 PM EDT
A
small study of Avalanche Biotechnologies Inc.'s (Nasdaq: AAVL) age-related
chronic eye disease treatment AVA-101 achieved its safety goal but
demonstrated only modest vision improvement sending the stock price plummeting $21.38 to $17.50.
